Lipocine (NASDAQ:LPCN) Director Buys 9,037 Shares of Stock

Lipocine Inc. (NASDAQ:LPCN) Director John Higuchi bought 9,037 shares of the business’s stock in a transaction on Tuesday, September 29th. The stock was purchased at an average cost of $2.15 per share, for a total transaction of $19,429.55. Following the transaction, the director owned 225,395 shares of the company’s stock, valued at $484,599.25. This trade represents a 4.18% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Lipocine Stock Performance

Shares of NASDAQ LPCN traded down $0.13 during trading on Thursday, reaching $2.07. The stock had a trading volume of 71,208 shares, compared to its average volume of 32,859. The company has a market cap of $17.06 million, a P/E ratio of -1.16 and a beta of 0.40. Lipocine Inc. has a fifty-two week low of $1.81 and a fifty-two week high of $12.37. The business’s 50-day moving average price is $2.17 and its 200-day moving average price is $2.73.

Lipocine (NASDAQ:LPCN) last announced its earnings results on Tuesday, August 4th. The specialty pharmaceutical company reported ($0.32) EPS for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.08. The company had revenue of $0.19 million during the quarter, compared to analysts’ expectations of $0.21 million. Lipocine had a negative return on equity of 64.75% and a negative net margin of 755.39%. Analysts forecast that Lipocine Inc. will post -1.54 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

LPCN has been the subject of several research reports. Weiss Ratings upgraded shares of Lipocine from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, September 24th. Wall Street Zen upgraded Lipocine from a “sell” rating to a “hold” rating in a report on Saturday, July 18th. HC Wainwright reaffirmed a “neutral” rating and issued a $4.00 price target on shares of Lipocine in a research report on Monday, September 21st. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Lipocine in a research note on Tuesday, September 22nd. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Lipocine has an average rating of “Hold” and an average price target of $4.00.

Institutional Investors Weigh In On Lipocine

Hedge funds and other institutional investors have recently modified their holdings of the company. Eversept Partners LP acquired a new stake in shares of Lipocine in the 1st quarter valued at $2,357,000. AIGH Capital Management LLC acquired a new position in shares of Lipocine during the first quarter worth $1,598,000. Stempoint Capital LP acquired a new position in shares of Lipocine during the first quarter worth $1,282,000. Seven Fleet Capital Management LP acquired a new position in shares of Lipocine during the first quarter worth $998,000. Finally, Persistent Asset Partners Ltd purchased a new position in Lipocine in the fourth quarter valued at $567,000. 9.11% of the stock is currently owned by institutional investors and hedge funds.

About Lipocine

Lipocine Inc is a clinical-stage biopharmaceutical company based in Salt Lake City, Utah, focused on developing oral therapies for conditions that have traditionally been treated with injections or other less convenient formulations. The company uses its proprietary Lip’ral drug-delivery technology to improve the absorption and administration of certain active pharmaceutical ingredients.

Lipocine’s lead product, TLANDO (testosterone undecanoate), is an oral testosterone-replacement therapy approved by the U.S.